Programs & Pipeline
Pompe Disease Clinical Trials
ATB200/AT2221: PHASE 1/2 SAFETY STUDY (ATB200-02 STUDY)
Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ATB200 Co-administered with Oral AT2221 in Patients with Pompe Disease
Active, not recruiting
Open-label, dose-escalation study of patients 18 to 65 years with a diagnosis of Pompe disease Pompe disease patients to assess if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
More information: www.clinicaltrials.gov: NCT02675465